Dirksen A - Search Results

1

Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ.

Seersholm N, Kok-Jensen A, Dirksen A. Seersholm N, et al. Among authors: dirksen a. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):1922-5. doi: 10.1164/ajrccm.152.6.8520756. Am J Respir Crit Care Med. 1995. PMID: 8520756

2

Patient-administered sequential spirometry in healthy volunteers and patients with alpha 1-antitrypsin deficiency.

Madsen F, Ulrik CS, Dirksen A, Hansen KK, Nielsen NH, Frølund L, Viskum K, Kok-Jensen A. Madsen F, et al. Among authors: dirksen a. Respir Med. 1996 Mar;90(3):131-8. doi: 10.1016/s0954-6111(96)90154-7. Respir Med. 1996. PMID: 8736204 Free article.

3

Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.

Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, Konietzko N. Seersholm N, et al. Among authors: dirksen a. Eur Respir J. 1997 Oct;10(10):2260-3. doi: 10.1183/09031936.97.10102260. Eur Respir J. 1997. PMID: 9387950 Free article. Clinical Trial.

4

Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease.

Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A. Hansen EF, et al. Among authors: dirksen a. Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1267-71. doi: 10.1164/ajrccm.159.4.9807121. Am J Respir Crit Care Med. 1999. PMID: 10194175

5

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.

Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J. Dirksen A, et al. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1468-72. doi: 10.1164/ajrccm.160.5.9901055. Am J Respir Crit Care Med. 1999. PMID: 10556107 Clinical Trial.

6

Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ.

Seersholm N, Wilcke JT, Kok-Jensen A, Dirksen A. Seersholm N, et al. Among authors: dirksen a. Am J Respir Crit Care Med. 2000 Jan;161(1):81-4. doi: 10.1164/ajrccm.161.1.9812131. Am J Respir Crit Care Med. 2000. PMID: 10619801

7

Attitudes toward an unsolicited approach in relation to status of genetic disease: exemplified by alpha(1)-antitrypsin deficiency.

Wilcke JT, Seersholm N, Kok-Jensen A, Dirksen A. Wilcke JT, et al. Among authors: dirksen a. Am J Med Genet. 2000 Sep 18;94(3):207-13. doi: 10.1002/1096-8628(20000918)94:3<207::aid-ajmg6>3.0.co;2-u. Am J Med Genet. 2000. PMID: 10995507

8

Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease.

Hansen EF, Vestbo J, Phanareth K, Kok-Jensen A, Dirksen A. Hansen EF, et al. Among authors: dirksen a. Am J Respir Crit Care Med. 2001 Mar;163(3 Pt 1):690-3. doi: 10.1164/ajrccm.163.3.2006120. Am J Respir Crit Care Med. 2001. PMID: 11254525

9

Decline in pulmonary function in patients with alpha 1-antitrypsin deficiency.

Evald T, Dirksen A, Keittelmann S, Viskum K, Kok-Jensen A. Evald T, et al. Among authors: dirksen a. Lung. 1990;168 Suppl:579-85. doi: 10.1007/BF02718180. Lung. 1990. PMID: 2117166

10

[New therapeutic possibilities in alpha 1-antitrypsin deficiency].

Kok-Jensen A, Dirksen A, Evald T, Keittelmann S, Viskum K. Kok-Jensen A, et al. Among authors: dirksen a. Ugeskr Laeger. 1990 Mar 26;152(13):906-8. Ugeskr Laeger. 1990. PMID: 2181756 Review. Danish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

254 results

Search Page